Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New surgical wash aims to cut joint infection risk in 7,600 replacement patients

NCT ID NCT05543941

Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new surgical irrigation solution called XPERIENCE can lower the risk of joint infection after hip or knee replacement better than the standard dilute Betadine wash. About 7,600 adults having primary hip or knee replacement will be randomly assigned to receive one of the two washes before the wound is closed. The main goal is to see how many develop an infection within 90 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
XPERIENCE Advanced Surgical Irrigation (a device/solution applied to the wound during surgery)
What this could lead to
If it works, this could provide a better way to prevent serious joint infections after hip or knee replacement surgery.
What could go wrong
This is a large trial, but it compares two existing approaches, so the difference may be small. The solution is new, so unexpected side effects or no benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 7,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female patients aged 18 years or older 2. Diagnosis of osteoarthritis, inflammatory arthritis, osteonecrosis, or post-traumatic arthritis to the affected joint. 3. Primary TKA, THA, and HR 4. Subjects receiving both cemented or uncemented orthopaedic implants 5. Willing and able to sign written consent, follow study protocol and attend follow-up Exclusion Criteria: 1. Inability or refusal to sign informed consent form 2. Non-English or French speaking, and no licensed translator, family member or substitute decision maker available. 3. Prior arthroplasty procedure to the affected joint 4. Procedures involving solid HA implants 5. Oncologic diagnosis to the affected joint. 6. Non-TKA, THA or HR prosthesis (i.e., hemiarthroplasty, unicompartmental arthroplasty etc.) 7. Allergy to any of the components of XP Advanced Surgical Irrigation 8. Allergy to iodine 9. Presence of concurrent active infection, primary immunodeficiency, history of uncontrolled HIV (CD4 count \<200 cells/uL), treatment with immunomodulatory medications for malignancy or autoimmune disease (with exception to inflammatory arthritis), chronic glucocorticosteroid use (≥20 mg of prednisone daily for at least 1 month with another cause of immunosuppression), and solid organ and/or bone marrow transplantation. 10. History of septic arthritis to the affected joint within two years of surgery(1). 11. History of steroid injection to the affected joint within the three months preceding surgery. 12. Simultaneous bilateral total joint arthroplasty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arthritic joint disease osteoarthritis osteoarthritis, hip osteoarthritis, knee osteonecrosis periprosthetic joint infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hip arthritis Hip osteoarthritis Knee arthritis Knee osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Quebec-Université Laval

    RECRUITING

    Québec, Quebec, Canada

  • Humber River Health

    RECRUITING

    Toronto, Ontario, Canada

  • Hôpital Maisonneuve-Rosemont

    RECRUITING

    Montreal, Quebec, Canada

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, Canada

  • London Health Sciences Center

    RECRUITING

    London, Ontario, Canada

  • St. Joseph's Health Centre

    RECRUITING

    Toronto, Ontario, Canada

  • The Ottawa Hospital

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • University of British Columbia

    RECRUITING

    Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.